Search

Your search keyword '"Cornelissen, Jan"' showing total 13 results
Start Over Author "Cornelissen, Jan" Journal cancer
13 results on '"Cornelissen, Jan"'

1. Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemia

Author

Loke, Justin, primary, Labopin, Myriam, additional, Craddock, Charles, additional, Cornelissen, Jan J., additional, Labussière‐Wallet, Hélène, additional, Wagner‐Drouet, Eva Maria, additional, Van Gorkom, Gwendolyn, additional, Schaap, Nicolaas P.M., additional, Kröger, Nicolaus M., additional, Veelken, Joan Hendrik, additional, Rovira, Montserrat, additional, Menard, Anne Lise, additional, Bug, Gesine, additional, Bazarbachi, Ali, additional, Giebel, Sebastian, additional, Brissot, Eolia, additional, Nagler, Arnon, additional, Esteve, Jordi, additional, and Mohty, Mohamad, additional

Published
2022
Full Text
View/download PDF

2. Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission—Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Author

Gorin, Norbert‐Claude, Labopin, Myriam, Czerw, Tomasz, Pabst, Thomas, Blaise, Didier, Dumas, Pierre‐Yves, Nemet, Damir, Arcese, William, Trisolini, Silvia Maria, Wu, Depei, Huynh, Anne, Zuckerman, Tsila, Meijer, Ellen, Cagirgan, Seckin, Cornelissen, Jan, Houhou, Mohamed, Polge, Emmanuelle, Mohty, Mohamad, and Nagler, Arnon

Published
2017
Full Text
View/download PDF

3. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Author

Yeshurun, Moshe, Labopin, Myriam, Blaise, Didier, Cornelissen, Jan J., Sengeloev, Henrik, Vindelov, Lars, Kuball, Juergen, Chevallier, Patrice, Craddock, Charles, Socie, Gerard, Bilger, Karin, Schouten, Harry C., Fegueux, Nathalie, Goker, Hakan, Maertens, Johan, Bunjes, Donald, Arnold, Renate, Nagler, Arnon, and Mohty, Mohamad

Published
2014
Full Text
View/download PDF

4. Post‐transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA‐identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Battipaglia, Giorgia, primary, Labopin, Myriam, additional, Hamladji, Rose‐Marie, additional, Blaise, Didier, additional, Chevallier, Patrice, additional, Brissot, Eolia, additional, Gerbitz, Armin, additional, Socié, Gerard, additional, Afanasyev, Boris, additional, Ciceri, Fabio, additional, Meijer, Ellen, additional, Koc, Yener, additional, Cornelissen, Jan J., additional, Huynh, Anne, additional, Ozdogu, Hakan, additional, Maertens, Johan, additional, Paul, Franciane, additional, Labussière‐Wallet, Hélène, additional, Ruggeri, Annalisa, additional, Aljurf, Mahmoud, additional, Bazarbachi, Ali, additional, Savani, Bipin, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2020
Full Text
View/download PDF

6. Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Wo

Author

Czerw, Tomasz, primary, Labopin, Myriam, additional, Giebel, Sebastian, additional, Socié, Gérard, additional, Volin, Liisa, additional, Fegueux, Nathalie, additional, Masszi, Tamás, additional, Blaise, Didier, additional, Chaganti, Sridhar, additional, Cornelissen, Jan J., additional, Passweg, Jakob, additional, Maertens, Johan, additional, Itälä-Remes, Maija, additional, Wu, Depei, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2018
Full Text
View/download PDF

7. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center

Author

Ciurea, Stefan O., primary, Labopin, Myriam, additional, Socie, Gerard, additional, Volin, Liisa, additional, Passweg, Jakob, additional, Chevallier, Patrice, additional, Beelen, Dietrich, additional, Milpied, Noel, additional, Blaise, Didier, additional, Cornelissen, Jan J., additional, Fegueux, Nathalie, additional, Polge, Emmanuelle, additional, Kongtim, Piyanuch, additional, Rondon, Gabriela, additional, Esteve, Jordi, additional, Mohty, Mohamad, additional, Savani, Bipin N., additional, Champlin, Richard E., additional, and Nagler, Arnon, additional

Published
2018
Full Text
View/download PDF

8. Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the Europe

Author

Gorin, Norbert-Claude, primary, Labopin, Myriam, additional, Czerw, Tomasz, additional, Pabst, Thomas, additional, Blaise, Didier, additional, Dumas, Pierre-Yves, additional, Nemet, Damir, additional, Arcese, William, additional, Trisolini, Silvia Maria, additional, Wu, Depei, additional, Huynh, Anne, additional, Zuckerman, Tsila, additional, Meijer, Ellen, additional, Cagirgan, Seckin, additional, Cornelissen, Jan, additional, Houhou, Mohamed, additional, Polge, Emmanuelle, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2016
Full Text
View/download PDF

9. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the

Author

Giebel, Sebastian, primary, Czyz, Anna, additional, Ottmann, Oliver, additional, Baron, Frederic, additional, Brissot, Eolia, additional, Ciceri, Fabio, additional, Cornelissen, Jan J., additional, Esteve, Jordi, additional, Gorin, Norbert-Claude, additional, Savani, Bipin, additional, Schmid, Christoph, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional

Published
2016
Full Text
View/download PDF

10. Long‐term follow‐up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Czerw, Tomasz, primary, Labopin, Myriam, additional, Gorin, Norbert‐Claude, additional, Giebel, Sebastian, additional, Blaise, Didier, additional, Meloni, Giovanna, additional, Pigneux, Arnaud, additional, Bosi, Alberto, additional, Veelken, Joan, additional, Ferrara, Felicetto, additional, Schaap, Nicolaas, additional, Lemoli, Roberto M., additional, Cornelissen, Jan J., additional, Beohou, Eric, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2016
Full Text
View/download PDF

11. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: A report from the Acute Leukemia Working Party of

Author

Yeshurun, Moshe, primary, Labopin, Myriam, additional, Blaise, Didier, additional, Cornelissen, Jan J., additional, Sengeloev, Henrik, additional, Vindelov, Lars, additional, Kuball, Juergen, additional, Chevallier, Patrice, additional, Craddock, Charles, additional, Socie, Gerard, additional, Bilger, Karin, additional, Schouten, Harry C., additional, Fegueux, Nathalie, additional, Goker, Hakan, additional, Maertens, Johan, additional, Bunjes, Donald, additional, Arnold, Renate, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional

Published
2013
Full Text
View/download PDF

12. Use of Tyrosine Kinase Inhibitors to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Position Statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Author

Jordi Esteve, Arnon Nagler, Fabio Ciceri, Sebastian Giebel, Norbert Claude Gorin, Jan J. Cornelissen, Bipin N. Savani, Oliver G. Ottmann, Frédéric Baron, Christoph Schmid, Eolia Brissot, Anna Czyż, Mohamad Mohty, Giebel, Sebastian, Czyz, Anna, Ottmann, Oliver, Baron, Frederic, Brissot, Eolia, Ciceri, Fabio, Cornelissen, Jan J., Esteve, Jordi, Gorin, Norbert Claude, Savani, Bipin, Schmid, Christoph, Mohty, Mohamad, Nagler, Arnon, and Hematology

Subjects
Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Dasatinib, Tyrosine kinase inhibitor, Hematopoietic stem cell transplantation, Philadelphia chromosome, 03 medical and health sciences, 0302 clinical medicine, Maintenance therapy, Internal medicine, medicine, Humans, Philadelphia Chromosome, Intensive care medicine, Protein Kinase Inhibitors, Societies, Medical, Acute leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, business.industry, Hematopoietic Stem Cell Transplantation, Cancer, Imatinib, Recommendation, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Nilotinib, medicine.disease, R1, respiratory tract diseases, 030220 oncology & carcinogenesis, Allogeneic hematopoietic stem cell transplantation, Neoplasm Recurrence, Local, business, 030215 immunology, medicine.drug
Abstract

Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a standard of care for patients with Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL). The introduction of tyrosine kinase inhibitors (TKIs) to first-line therapy has improved overall outcomes; however, a significant proportion of patients still relapse after alloHSCT. Posttransplant TKI maintenance was demonstrated to reduce the risk of relapse in a large retrospective study and, therefore, should be considered a valuable option. This consensus paper, written on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, presents an overview of clinical studies on the use of TKIs after alloHSCT and proposes practical recommendations regarding the choice of TKI, treatment timing, and dosage. It is hoped that these recommendations will become the state of art in this field and, more importantly, lead to a reduction of Ph-positive ALL relapse after alloHSCT. Cancer 2016;122:2941-2951. © 2016 American Cancer Society.

Published
2016

13. Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Author

Battipaglia G, Labopin M, Hamladji RM, Blaise D, Chevallier P, Brissot E, Gerbitz A, Socié G, Afanasyev B, Ciceri F, Meijer E, Koc Y, Cornelissen JJ, Huynh A, Ozdogu H, Maertens J, Paul F, Labussière-Wallet H, Ruggeri A, Aljurf M, Bazarbachi A, Savani B, Nagler A, and Mohty M

Subjects
Adolescent, Adult, Aged, Feasibility Studies, Female, Follow-Up Studies, Graft vs Host Disease epidemiology, Humans, Incidence, Male, Middle Aged, Retrospective Studies, Transplantation, Homologous methods, Treatment Outcome, Young Adult, Antilymphocyte Serum administration & dosage, Blood Donors, Cyclophosphamide administration & dosage, Graft vs Host Disease prevention & control, HLA Antigens immunology, Hematopoietic Stem Cell Transplantation adverse effects, Hematopoietic Stem Cell Transplantation methods, Immunosuppressive Agents administration & dosage, Leukemia, Myeloid, Acute surgery, Siblings
Abstract

Background: Graft-versus-host disease (GVHD) is a major complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Addition of antithymocyte globulin (ATG) or post-transplantation cyclophosphamide (PTCY) to standard immunosuppressive agents reduces GVHD in different donor settings., Methods: We compared the outcomes of adults with acute myeloid leukemia undergoing allo-HSCT from HLA-identical sibling donors after the use of PTCY (n = 197) or ATG (n = 1913)., Results: Patients in the PTCY group were younger than those in the ATG group (median age, 47 vs 54 years; P < .01). Peripheral blood was the most frequently used stem cell source, being significantly more frequent in the ATG group than in the PTCY group (95% vs 70% P < .01). The conditioning regimen was more frequently myeloablative in the PTCY group than in the ATG group (59% vs 48%; P < .01). Time to neutrophil engraftment was shorter in the ATG group than in the PTCY group (17 vs 20 days; P < .01). No differences were observed according to the other transplantation outcomes, except for chronic GVHD of all grades and extensive chronic GVHD at 2 years, which were significantly lower in the ATG group compared with the PTCY group (P < .02)., Conclusion: PTCY is feasible in an HLA-identical sibling setting, and despite similar outcomes, ATG may be associated with lower incidence of chronic GVHD., (© 2020 American Cancer Society.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results